Major insurers are now seeking smaller, single-digit premium increases for Affordable Care Act (ACA) plans; drug makers and distributors of painkillers being sued for their alleged role in the opioid crisis are trying to build goodwill by giving grants and donations to hard-hit counties, cities, and states that are filing the lawsuits; hundreds of people have sued Bristol-Myers Squibb and Otsuka, alleging that the drug Abilify caused compulsive behavior.
The Affordable Care Act (ACA) marketplace may finally be stabilizing. For years, insurers have made large hikes to premiums for ACA plans, but major insurers are now seeking smaller single-digit increases, according to The Wall Street Journal. Some big insurers in Texas, Illinois, Arizona, and North Carolina are even seeking reductions. However, there are still plans that will see large increases to reflect the health of the members they are serving.
Communities across the country are filing lawsuits against drug makers and distributors of painkillers for their alleged role in the ongoing opioid epidemic. Now, these same companies are giving grants and donations to those very same communities, cities, and states. Bloomberg reported that the companies are not only trying to build goodwill ahead of potential settlements, but the charity could help them reduce their tax bills. For the areas hit by the opioid epidemic, the money is going to things like prevention programs.
Hundreds of people have sued Bristol-Myers Squibb and Otsuka, alleging that their drug aripiprazole (Abilify) caused compulsive behavior. The lawsuits claim the drug, an antipsychotic, caused them to gamble, eat, or have sex compulsively, reported STAT. The exact reason why the drug causes such behavior in a handful of the millions of people who take the drug has not been discovered yet. The FDA issued a safety warning in 2016 acknowledging that some patients have reported these uncontrollable urges. Abilify was first approved to treat schizophrenia and has since been approved to treat bipolar disorder, irritability associated with autistic disorder, Tourette syndrome, and major depressive disorder.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
2 Commerce Drive
Cranbury, NJ 08512